PI3Kδ/γ inhibition promotes human CART cell epigenetic and metabolic reprogramming to enhance antitumor cytotoxicity

Current limitations in using chimeric antigen receptor T(CART) cells to treat patients with hematological cancers include limited expansion and persistence in vivo that contribute to cancer relapse. Patients with chronic lymphocytic leukemia (CLL) have terminally differentiated T cells with an exhau...

Celý popis

Podrobná bibliografie

Vydáno v:	Blood Ročník 139; číslo 4; s. 523
Hlavní autoři:	Funk, Christopher Ronald, Wang, Shuhua, Chen, Kevin Z, Waller, Alexandra, Sharma, Aditi, Edgar, Claudia L, Gupta, Vikas A, Chandrakasan, Shanmuganathan, Zoine, Jaquelyn T, Fedanov, Andrew, Raikar, Sunil S, Koff, Jean L, Flowers, Christopher R, Coma, Silvia, Pachter, Jonathan A, Ravindranathan, Sruthi, Spencer, H Trent, Shanmugam, Mala, Waller, Edmund K
Médium:	Journal Article
Jazyk:	angličtina
Vydáno:	United States 27.01.2022
Témata:	Animals Cells, Cultured Cellular Reprogramming Techniques - methods Class I Phosphatidylinositol 3-Kinases - antagonists & inhibitors Class I Phosphatidylinositol 3-Kinases - metabolism Class Ib Phosphatidylinositol 3-Kinase - metabolism Epigenesis, Genetic Humans Immunotherapy, Adoptive - methods Isoquinolines - therapeutic use Leukemia, Lymphocytic, Chronic, B-Cell - genetics Leukemia, Lymphocytic, Chronic, B-Cell - therapy Mice Phosphoinositide-3 Kinase Inhibitors - therapeutic use Purines - therapeutic use
ISSN:	1528-0020, 1528-0020
On-line přístup:	Zjistit podrobnosti o přístupu
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!